On May 13, 2024 Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab reported the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares (Press release, Genmab, MAY 13, 2024, View Source [SID1234643141]).
The share buy-back program is expected to be completed no later than December 16, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following transactions were executed under the program from May 6, 2024 to May 10, 2024:

Trading Platform No. of shares Average price (DKK) Total value (DKK)
Accumulated through
last announcement 689,510 1,393,154,997.08
May 6, 2024 XCSE
CEUX
AQEU
TQEX
Total 0 0.00 0.00
May 7, 2024 XCSE 0 0
CEUX 35 1,998.00
AQEU 0 0
TQEX 0 0
Total 35 1,998.00 69,930.00
May 8, 2024 XCSE 28 2,013.00
CEUX 55 2,015.45
AQEU 0 0
TQEX 37 2,002.00
Total 120 2,010.73 241,288.00
May 9, 2024 XCSE
CEUX
AQEU
TQEX
Total 0 0.00 0.00
May 10, 2024 XCSE
CEUX
AQEU
TQEX
Total 0 0.00 0.00
Total 155 311,218.00
Accumulated under the program 689,665 1,393,466,215.08

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 1,538,803 shares as treasury shares, corresponding to 2.33% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour Regulation." Further details on the terms of the share buy-back program can be found in our company announcement no. 22 dated March 15, 2024.